ArticleBMC genomic data2026
Preliminary genomic assessment of invasive Streptococcus pneumoniae serotype 3 isolates in Malaysia.
Article in BMC genomic data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundStreptococcus pneumoniae is a pathogen responsible for invasive pneumococcal disease (IPD) among young children, the elderly, and immunocompromised individuals. The polysaccharide capsule is a main virulence factor that defines pneumococcal serotypes, among which serotype 3 is highly invasive and associated with severe clinical outcomes. Experience from countries that implemented pneumococcal conjugate vaccines (PCVs) earlier have demonstrated a shift in serotype distribution, with a notable increase in serotype 3 following vaccine rollout. Given the persistence of serotype 3 despite widespread vaccination, genomic studies have been conducted in different countries to better understand the serotype. This pilot study utilizes whole genome sequencing (WGS) analysis to provide preliminary insights into the population structure and resistance profiles of serotype 3 clones in Malaysia.
resultsFive S. pneumoniae serotype 3 isolates were recovered from blood specimens of Malaysian pediatric patients with invasive pneumococcal infections between 2022 and 2023. All isolates were confirmed as serotype 3 by phenotypic testing and genomic identification. Whole genome sequencing that involved Illumina NovaSeq6000 sequencing platform generated 470,029–779,194 reads, with > 35 mean Phred score, average GC content of 39–40%, and ≥ 99.9% genome completeness. Genomic analyses revealed genome sizes ranging from 1.94 to 2.00 Mb, comprising 56 to 80 contigs, with N50 values ranging from 64,020 to 103,653 bp. Genomic characterization based on single nucleotide polymorphism (SNP) identified three distinct lineages in Malaysia: GPSC12/ST180, GPSC43/ST6011, and GPSC83/ST1377. Antimicrobial susceptibility testing identified a multidrug-resistant GPSC43/ST6011 isolate, resistant to erythromycin, clindamycin, tetracycline, and trimethoprim–sulfamethoxazole, corresponding to the presence of ermB, tetM_12, and mutations in folA and folP. The remaining isolates were phenotypically susceptible to all tested antimicrobials without resistance determinants detected in the genomes. Despite variation in penicillin-binding protein (pbp) gene profiles, all isolates remained susceptible to beta-lactam antibiotics.
conclusionThe study presents a preliminary genomic characterization of invasive serotype 3 S. pneumoniae in Malaysia. The identification of distinct lineages and a multidrug-resistant clone highlight the value of genomic data in understanding local pneumococcal epidemiology. A nationwide genomic surveillance is important to monitor emerging high-risk clones and antimicrobial resistome to combat invasive diseases caused by serotype 3 S. pneumoniae in Malaysia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.